Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.

Background And Aims: Biosimilars have been available in the European Union (EU) since 2006. However, their uptake in routine care is heterogeneous across countries. The aim of the present study was to compare the safety information of biosimilars and their originators based on the information in the European risk management plan (RMP).